suMMARY Fifteen patients with congestive cardiomyopathy who had improved conspicuously on chronic administration of a beta-blocker were studied after withdrawal of the drug. In six patients there was a pronounced deterioration of their clinical condition, and in all of the remaining patients there was a significant decrease in ejection fraction, and signs of compromised diastolic function with pathological apex curves and an increase in third heart sound. All these changes were reversed within a few weeks to a few months after readministration of beta-blocking drugs. This study supports the idea that an aetiological factor in congestive cardiomyopathy may be a pathological response to sympathetic stimulation which could be partly controlled by administration of beta-blocking drugs.
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An improvement in myocardial function and general condition with chronic beta-blockade in patients with congestive cardiomyopathy (COCM) was first reported in 1975,1 and this has been confirmed in a more extensive recent study.2 3 It has been known for many years that in patients with heart failure there is a compensatory increase in sympathetic nervous activity to counteract the depressed myocardial function.4 Furthermore, betablockade is thought to aggravate heart failure and this treatment is said to be contraindicated in such patients. Taking this into account, the finding that beta-blocking agents could cause an improvement in myocardial function in patients with congestive cardiomyopathy and heart failure was surprising and unexpected.
In this study beta-blockade was withdrawn in patients with COCM after long-term administration. This was done for two reasons. First, the effects of withdrawal should give useful information about the role of beta-blockade in the improvement in myocardial function after long-term treatment. Second, valuable information could be obtained about the mechanisms underlying the observed beneficial effect of beta-blockade in these patients. A, alprenolol; M, metoprolol; P, practolol; PR, propranolol; EF, ejection fraction; RFW/H ratio, rapid filling wave ratio; a/H ratio, "a" wave ratio; 0, unchanged; 1', increased; 4,, decreased; -, not investigated; AF, atrial fibrillation.
resting LVEDP, and a reduction of the exercise LVEDP; the EF had increased to 0O58 and the LVEDD had decreased to 4-8 cm (Fig. 2) . During the next two years the patient continued to improve, after which he defaulted from follow-up. Eighteen months later he was readmitted in severe biventricular failure, which had developed two months after accidental withdrawal of alprenolol. Again, the echocardiographic findings were grossly abnormal ( Fig. 3) with an LVEDD of 6-7 cm, an EF of 0-23, and signs of mitral regurgitation. The findings were similar to those noted before betablockade was instituted. This male patient, previously healthy except for pulmonary tuberculosis controlled by chemotherapy, had suddenly developed biventricular cardiac failure six months before the start of beta-blockade. His condition deteriorated progressively despite treatment with digoxin and frusemide, and his functional grade was IV when he was considered for inclusion in the study.
Haemodynamic investigations at this time showed a cardiac index of 1-2 I/min per m2, and a grossly dilated left ventricle with an LVEDD of 8-0 cm and an EF of 0-18 were shown echocardiographically. A loud third heart sound was present and was recorded on the phonocardiogram. Metoprolol was given initially in very low dosage. This was eventually increased to 25 mg twice daily which was well tolerated and the patient's condition improved with an increase in exercise capacity. The third heart sound decreased considerably. The EF increased to 0A42, but the LVEDD decreased only slightly to 7T2 cm. According to the study procedure, active treatment was withdrawn after six months and the patient carefully supervised iñ 5Hz . 5.. fibre shortening (mean VCF) was significantly reduced in six of the patients but was unchanged in five and increased in one of the patients studied.
The size of the left atrium was increased in four of the patients, slightly increased in two, and unchanged in the others. The LVET was decreased in half of the patients studied and increased or unchanged in the others. All patients but one showed an increase in heart rate after beta-blockade withdrawal and the overall change in heart rate was significant for the group (p < 001) (mean heart Beta-blockade withdrawal in congestive cardiomyopathy rate 71 +3 on beta-blockade; 88 +4 beats per minute after withdrawal).
The recorded amplitude of the third heart sound increased from 1 ±04 to 6 ±2 mm (p < 0 05) and was much increased in seven of the patients (Fig. 6) . Seven of the patients had no measurable third heart sound on beta-blockade and it returned in five of these patients after discontinuation of treatment. Though several of the patients also showed an increase in the fourth heart sound amplitude, the changes in this index were more variable. The changes in RFW/H ratio are shown in Fig. 7 . A significant increase in RFW occurred (p < 0-5) and all but two of the patients studied showed an individual increase. Changes in a/H ratio increased in some patients and decreased in others so that the mean value for the group was not changed with withdrawal of beta-blockade. Three of the patients showing a reduction in the "a" wave (cases 1, 6, and 28) had a clear increase in RFW.
During long-term treatment with beta-blockade two patients who had been on beta-blockade for 24 months and 12 months discontinued treatment without informing us. This was done by one (case 5) when the toxic effects of practolol were reported, and by the other (case 6) because of persisting exertional dyspnoea. After discontinuation of betablockade both developed severe cardiac failure and were brought to hospital with pulmonary oedema.
When beta-blockade was reinstituted there were no further attacks of pulmonary oedema in either of them.
Discussion
The present study shows that myocardial function in congestive cardiomyopathy can be impaired by withdrawal of beta-blockers. Six of the 15 patients in the study showed a distinct deterioration in their clinical condition, with the appearance of increased dyspnoea, and three of the patients showed other signs of severe cardiac failure, such as hypotension, poor peripheral circulation, and cardiogenic shock. One of the patients who developed increased dyspnoea died suddenly 41 days after beta-blockade was discontinued. Cardiogenic shock developed two weeks after withdrawal in another patient. The ejection fraction, as measured from the echocardiogram, was decreased in 11 of the 13 patients in whom it was measured. Eight patients showed an increase in rapid filling wave and six patients a clear increase in the amplitude of the third heart sound. It appeared that the patients who had had the most dramatic improvement with beta-blockade showed the most severe deterioration after its withdrawal. The development of pulmonary oedema in the two patients who stopped treatment without our knowledge is in accord with the other observations following planned beta-blockade withdrawal. The results from this study strongly support the findings of Fig. 7 Rapid filling wave ratio (RFW/H ratio) and "a" wave ratio (a/H ratio) in patients with congestive cardiomyopathy before (S) and during (B) '-3 A deterioration in myocardial function after discontinuation of chronic beta-blockade indicates that the treatment has not been curative. In the patients whose clinical condition deteriorated with the appearance of severe dyspnoea this appeared in two of them very soon after discontinuation of betablockade while there was a slower deterioration in the others. This suggests that impaired cardiac function does not correlate directly with the fall in tissue drug concentration in all patients. Betablockade, by reducing heart rate and myocardial work, could have beneficial effects on energy metabolism and heart function. The reduction of metabolic demand induced by beta-blockade would be beneficial if the myopathic heart cells were deficient in energy-yielding substrates, such as ATP, and at risk of accumulation of metabolites, such as lactate and NADH+. Metabolic overactivity in the myopathic cells could be caused by inappropriately high sympathetic activity or increased sensitivity of the cells to sympathetic stimulation. The delayed clinical deterioration in some patients could be related to structural changes within the myopathic heart cells in the absence of the protective effects of beta-blockade. It is known that catecholamines have a direct stimulatory effect on processes of protein synthesis in the heart, and it has been suggested that the synthesis of a defective contractile protein could be a consequence of increased sensitivity to beta,-stimulation.7 It seems unlikely that a rebound phenomenon after withdrawal of beta-blockade was of importance in this study. In dogs, haemodynamic and metabolic responses to abrupt withdrawal of beta-blockade usually appear within 24 to 48 hours,8 and in man it has been reported that the greatest sensitivity to catecholamines after withdrawal of long-term betablockade occurs within four to six days.9 Symptoms such as chest pain and ventricular arrhythmias in patients with ischaemic heart disease have been reported as occurring immediately after chronic treatment is stopped.10
In conclusion, the present study strongly supports the hypothesis that sympathetic nervous activity, in some way, plays a role in the development of congestive cardiomyopathy. Any group of patients with congestive cardiomyopathy is heterogeneous and the role of catecholamines in the development of the disease and the appearance of symptoms may be variable. Chronic beta-blockade will produce clinical improvement in some patients but not in others.3 Similarly, withdrawal of beta-blockade caused a distinct deterioration in some of the patients in this study, but had little influence on the others.
